FDA approves first treatment to delay type 1 diabetes.


LINCOLN, Neb. (KLKN) – The food and drug administration has approved a new treatment that could help millions of people at risk for type one diabetes.

Provention-bio and Sanofi have created Tzield, a biologic therapy.

It delays the body’s misdirected attack on its own insulin-producing cells by protecting these cells.

It buys people more time before becoming dependent on insulin injections.

In clinical trials, the drug delayed onset by two years.

The FDA approved the treatment for people eight and over who are at risk for type one diabetes.

It is given through an intravenous infusion every day for two weeks.

The most common side effects were low white blood cell and lymph cells, rashes, and headaches.

Categories: Consumer News, Health, Nebraska News, News, US & World